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Methylphenidate Normalizes Frontocingulate
Underactivation During Error Processing in
Attention-Deficit/Hyperactivity Disorder
Katya Rubia, Rozmin Halari, Abdul-Majeed Mohammad, Eric Taylor, and Michael Brammer
Background: Childrenwith attention-deficit/hyperactivity disorder (ADHD) have deficits in performancemonitoring often improvedwith
the indirect catecholamine agonist methylphenidate (MPH). We used functional magnetic resonance imaging to investigate the effects of
single-doseMPH on activation of error processing brain areas in medication-naive boys with ADHD during a stop task that elicits 50% error
rates.
Methods: Twelve medication-naive boys with ADHD were scanned twice, under either a single clinical dose of MPH or placebo, in a
randomized, double-blind design while they performed an individually adjusted tracking stop task, designed to elicit 50% failures. Brain
activation was compared within patients under either drug condition. To test for potential normalization effects of MPH, brain activation in
ADHD patients under either drug condition was compared with that of 13 healthy age-matched boys.
Results: During failed inhibition, boys with ADHD under placebo relative to control subjects showed reduced brain activation in perfor-
mancemonitoring areas of dorsomedial and left ventrolateral prefrontal cortices, thalamus, cingulate, and parietal regions. MPH, relative to
placebo, upregulated activation in these brain regions within patients and normalized all activation differences between patients and
control subjects. During successful inhibition, MPH normalized reduced activation observed in patients under placebo compared with
control subjects in parietotemporal and cerebellar regions.
Conclusions: MPH normalized brain dysfunction in medication-naive ADHD boys relative to control subjects in typical brain areas of
performancemonitoring, comprising left ventrolateral anddorsomedial frontal andparietal cortices. This could underlie the amelioration of
MPH of attention and academic performance in ADHD.
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A ttention-deficit/hyperactivity disorder (ADHD) is defined byage-inappropriate inattention, impulsiveness, and hyperac-tivity (DSM-IV) (1). Childrenwith ADHD have deficits in tasks
of cognitive control (2,3) concomitant with reduced activation in
inferior frontostriatal, cingulate, and parieto-temporal regions (4–
11). Psychostimulants, such as methylphenidate (MPH), are the
most effective, first-choice treatment for ADHD, improving symp-
toms in70%ofpatients (12,13).Nevertheless, little is knownon their
mechanism of action. MPH is a catecholamine reuptake inhibitor
with stronger dopaminergic effects subcortically and catechol-
amine effects in cortical regions (12,14). The behavioral and cogni-
tive features of ADHDare thought to bemediated at least in part by
a catecholamine dysfunction, with evidence for abnormal striatal
dopamine transporter (DAT) levels anddopamineavailability (15). It
has been argued that poor inhibitory control in ADHD childrenmay
be related to poor performance monitoring, given that ADHD chil-
dren, unlike control subjects, donot slowdownafter errors (16–18).
MPH has been shown to improve inhibitory performance as well as
errormonitoring inADHDchildren (17,19) and toupregulate abnor-
mally low error-related evoked potentials, presumably reflecting
anterior cingulate/medial frontal activity (20,21). Surprisingly, how-
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doi:10.1016/j.biopsych.2011.04.018ver, only two previous functional magnetic resonance imaging
fMRI) studies have investigated the acute effects ofMPH on neuro-
unctional networks of motor response inhibition in previously
edicated childrenwith ADHD, finding reduced upregulationwith
PH in defined regions of interest of caudate, anterior cingulate
nd frontal brain regions (22,23). Usingwhole-brain analyses, single
oses of MPH have shown to upregulate and normalize frontal,
triatal and cingulate activation in children with ADHD during di-
ided attention (24), interference inhibition (25), sustained atten-
ion (26) and time estimation (27). No fMRI study, however, has
ested forMPH effects onmotor response inhibition inmedication-
aive children with ADHD nor on neural networks of error process-
ng.
In this study, we investigated the effect of MPH on neural pro-
esses of errormonitoring inmedication-naive childrenwith ADHD
y use of a challenging tracking stop task, optimally suited to test
or error detection networks because it ensures 50% of inhibition
ailures in every subject.
To overcome the limitations of previous ADHD fMRI studies of
nhibition of regions of interest analyses and/or a medication his-
ory in patients (22,23,28), we conducted a double-blind, random-
zed, placebo-controlled pharmacologic fMRI experiment of the
ffects of a single acute clinical dose ofMPH in 12medication-naive
oys with ADHD. Furthermore, we compared brain activation in
DHD patients at baseline and after MPH with that of a healthy
ge-matched group of control children to test for potential amelio-
ation or normalization effects of MPH on error-related and inhibi-
ory brain dysfunctions during the placebo condition. Given our
revious findings of upregulation and normalization of frontostria-
al brain activation inmedication-naive childrenwith ADHDduring
ustained attention, interference inhibition and time estimation
25–27), we hypothesized that MPHwould upregulate and normal-
ze typically underactivated areas of error detection in ADHD pa-
BIOL PSYCHIATRY 2011;70:255–262
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wtients relative to control subjects in ventromedial and lateral pre-
frontal, posterior cingulate, and parietal regions (5,6,8,29). We
furthermore hypothesized that MPH would normalize typical right
inferior prefrontal and caudate underactivation during inhibition in
ADHD compared with healthy children (5–8,29).
Methods andMaterials
Subjects
Twelve medication-naïve, right-handed boys aged 10 to 15
years (mean age 13, SD 1) who met clinical diagnostic criteria
for the combined (inattentive/hyperactive) subtypeofADHD (DSM-
IV) were recruited through clinics. Clinical diagnosis of ADHD was
established through interviews with an experienced child psychia-
trist (A-MM) using the standardizedMaudsley Diagnostic Interview
to check for presence or absence of diagnostic criteria for any
mental disorder as set out by DSM-IV (30). Exclusion criteria were
lifetime comorbidity with any other psychiatric disorder, except for
conduct/oppositional defiant disorder (present in one patient), as
well as learning disability and specific reading disorder, neurologi-
cal abnormalities, epilepsy, drug or substance abuse, and previous
exposure to stimulant medication. Patients with ADHD also had to
score above cutoff for hyperactive/inattentive symptoms on the
Strengths and Difficulties Questionnaire for Parents (SDQ) (31). Pa-
tients were scanned twice, in a randomized, counterbalanced fash-
ion, 1 week apart, 1 hour after either .3 mg/kg of MPH administra-
tion or placebo (vitamin C, 100 mg).
Thirteenmale right-handed adolescent boys in the age range of
11 to 16 years (mean age  13, SD  1) were recruited through
advertisements in the same geographic areas of South London to
ensure similar socioeconomic status and were scanned once. They
scored below cutoff for behavioral problems in the SDQandhadno
history of psychiatric disorder.
All participants were above the fifth percentile on the Raven
progressive matrices performance IQ (32) (IQ mean estimate con-
trols  100, SD  14; ADHD  91, SD  9) and paid £30 for
articipation. Parental and child informed consent/assent and ap-
roval from the local ethical committee was obtained.
Univariate analyses of variance (ANOVAs) showed no group dif-
erencesbetweenboyswithandwithoutADHDfor age [F (1,25)2,
 .2] but did for IQ [F (1,25)  8, p  .009]. IQ is associated with
DHD in the general population (33,34). We purposely did not
atch groups for IQ because matching ADHD and control groups
or IQ would have created unrepresentative groups and therefore
e misguided (35). Furthermore, IQ was significantly negatively
orrelated with the SDQ scores for inattention and hyperactivity
r.5, p .001). We did not covary for IQ because when groups
are not randomly selected, covarying for a variable that differs
between groups violates the standard assumptions for analysis of
covariance. When the covariate is intrinsic to the condition, it be-
comes meaningless to “adjust” group effects for differences in the
covariate because it would alter the group effect in potentially
problematic ways, leading to spurious results (35,36).
fMRI Paradigm: Stop Task
The rapid, mixed-trial, event-related fMRI design was practiced
by subjects once before scanning. The visual tracking stop task
requireswithholdingof amotor response to ago stimuluswhen it is
followed unpredictably by a stop signal (8,37,38). The basic task is a
choice reaction time task (left and right pointing arrows: go signals)
with a mean intertrial-interval of 1.8 sec (156 go trials). In 20% of
trials, pseudo-randomly interspersed, the go signals are followed
(about 250ms later) by arrows pointing upwards (stop signals), and h
ww.sobp.org/journalubjects have to inhibit their motor responses (40 stop trials). A
racking algorithm changes the time interval between go-signal
nd stop-signal onsets according to each subject’s inhibitory per-
ormance to ensure that the task is equally challenging for each
ndividual and to provide 50% successful and 50% unsuccessful
nhibition trials at every moment of the task.
MRI Image Acquisition
Gradient-echo echoplanar magnetic resonance imaging data
ere acquired on a GE Signa 1.5-T Horizon LX System (General
lectric,Milwaukee,Wisconsin) at theMaudsleyHospital, London.A
uadrature birdcage head coil was used for radio-frequency trans-
ission and reception. During the 6-min run of the stop task, in
ach of 16 noncontiguous planes parallel to the anterior–posterior
ommissural, 196 T2*-weighted magnetic resonance images de-
icting blood oxygen–level dependent (BOLD) contrast covering
he whole brain were acquired with echo time  40 msec, repeti-
ion time 1.8 sec, flip angle 90°, in-plane resolution 3.1 mm,
lice thickness  7 mm, slice skip  .7 mm, providing complete
rain coverage.
MRI Image Analysis
At the individual subject level, a standard general linear model-
ng approach was used to obtain estimates of the response size
beta) to each of the two stop task conditions (successful and un-
uccessful stop trials) against an implicit baseline (go trials). Follow-
ng transformation of the fMRI data for each individual into stan-
ard space and smoothing with a three-dimensional 7-mm full
idth at halfmaximumGaussian filter, the experimentalmodelwas
onvolved for each conditionwith gamma variate functions having
eak responses at 4 and 8 sec following stimulus onset to accom-
odate variability in BOLD response timing. By fitting these con-
olved model components to the time series at each voxel, beta
stimates were obtained for each effect of interest. The standard
rrors of these beta estimates were computed nonparametrically
sing a bootstrap procedure designed to operate on time series
ata, containing serial dependencies, with repeated deterministic
experimentally determined) effects. This method is outlined in
etail in a previous work (39). Two hundred bootstraps at each
oxel were used to estimate parameter standard errors. Using the
ombined parameter estimates over all conditions, themean fitted
ime series was also computed and, from the combined bootstrap
arameter estimates for each bootstrap, the 95% confidence limits
n the fitted time series was computed.
The second-level analysis proceeded by computing either the
roup differences (patients and controls) or the drug condition
ifferences (placebo, MPH) within patients at each voxel and the
tandard error of this difference (using the bootstrap estimates
erived earlier). The significance of these differences was then
ested in three ways: 1) a simple parametric random effects (paired
) test, using only the group difference/placebo-MPH effect size
ifferences; 2) a permutation test of the same random effects t
tatistic in which the null distribution was estimated by randomly
wapping the signs of the differences (we used 40,000 permuta-
ions per voxel to obtain a confidence limit of .0007–.0013 for p
alue of .001); and 3) a mixed-effects test using both the effect size
ifferences and their subject-level standard errors to accommodate
rst (subject) level heteroscedasticity (40). This was also conducted
sing 40,000 permutations per voxel.
In addition to voxelwise maps, cluster-level inference on the
ontrast (beta) values was performed at a family-wise error cor-
ected threshold of p  .05 using the Threshold-Free Cluster En-
ancement method proposed by Smith and Nichols (41). This clus-
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experimental condition.
Results
Performance
The probability of inhibition was about 50% in all subjects with
no significant group differences, showing that the task algorithm
worked [F(1,38) 1; p .3; Table 1].
A multivariate ANOVA between control subjects and ADHD pa-
tients under either drug condition showed a trend for a significant
group effect [F (8,62)  2, p  .09] due to a significant univariate
group effect in the standard deviation to go trials [F (2,34) 5, p
02], which were higher in patients under either medication condi-
ion compared with control subjects (p  .05). Post hoc tests fur-
hermore revealed a trend forMPH comparedwith placebo to slow
own reaction timeswithin ADHDpatients to both go (p .06) and
ost-error go trials (both p .07) (Table 1).
Brain Activation
Motion
Multivariate ANOVA showed no significant group differences
between control subjects and ADHD patients under either drug
condition in mean or maximum rotation or translation parameters
in the x, y, or z dimensions [F (2,38) .9, p .5].
Within-Group Brain Activations
FailedStop–GoContrast. Control subjects activated relatively
large clusters in left and right inferior frontal cortex (IFC)/anterior
insula, medial frontal/anterior cingulate cortex (MFC/ACC), precen-
tral, inferior parietal, middle and superior temporal areas, posterior
thalamus and caudate, parahippocampal gyri, precuneus/posterior
cingulate, occipital, and cerebellar areas.
Table 1. Main Variables of the Stop Task by Group
Performance
Measure
Healthy
Controls
(n 13)
ADHD
Placebo
(n 12)
ADHD
MPH
(n 12)
PI (in %) 49 (6) 47 (5) 52 (10)
MRT go trials (msec) 772 (118) 719 (104) 821 (154)
SD go trials (msec) 202 (52) 254 (63) 295 (103)
SSRT (msec) 205 (147) 143 (216) 166 (214)
Post-error go MRT 756 (98) 695 (123) 783 (129)
ADHD, attention-deficit/hyperactivity disorder; MPH, methylphenidate;
MRT, mean reaction time to go trials; SSRT, stop signal reaction time, calcu-
lated by subtracting themean stop signal delay (the average time between
go and stop signal, at which the subject managed to inhibit to 50% of trials)
from the MRT to go trials.
Figure 1. Increasedbrain activationwith the single dose ofmethylphenidate
during inhibition failures.Within-groupanalysis of variance inboyswith atte
the inhibition failure condition at family-wise error-corrected cluster-level co
n left inferior prefrontal cortex reaching intoputamen, in right inferior fronta
ortex, and in right inferior parietal lobe and precuneus. No brain regions w
ctivation differences between drug conditionswere observed for the successful
f the brain.Activation in ADHD patients under placebo was in MFC and
uperior temporal cortex reaching into anterior and posterior in-
ula, caudate, and inferior parietal and occipital cortex.
Activation in ADHD patients under MPHwas in a large cluster of
CC and MFC, in left and right IFC/anterior insula, left premotor
ortex, right basal ganglia, bilateral middle and superior temporal,
nferior parietal and occipital areas, hippocampal gyri, posterior
ingulate, precuneus, and cerebellum (Figure S1 in Supplement 1).
Successful Stop–Go Contrast. Activation in healthy control
oys was in a large cluster comprising left and right orbital and IFC,
orsolateral andMFC, insula, basal ganglia, hippocampus, posterior
halamic regions, pre- and postcentral gyri, inferior and superior
arietal, temporal and occipital cortices, precuneus, and posterior
ingulate.
Activation in ADHDpatients under placebowas in small clusters
n right MFC, supplementary motor area (SMA), right superior tem-
oral, postcentral, left inferior and superior parietal, and occipital
ortices.
Activation in ADHD patients under the MPH condition was in
uperior and MFC/ACC, right globus pallidus and putamen, right
uperior temporal and superior and inferior parietal cortex, poste-
ior insula, and left cerebellum (Figure S1 in Supplement 1).
NOVAWithin-Patient Comparisons in Brain Activation
etween the Placebo and theMPH Conditions
Failed Stop–Go Contrast. MPH contrasted with placebo elic-
ted enhanced activation in left IFC, reaching into insula and puta-
en; in right IFC reaching into insula, putamen, and caudate; in left
edial frontal lobe; and in left inferior parietal, precuneus, and
ccipital regions (Figure 1, Table 2). The placebo condition elicited
o enhanced activation over MPH.
To investigate whether brain regions that differed with MPH
ere associated with task performance, statistical measures of the
OLD response were extracted for each subject in each ANOVA
luster and thencorrelatedwithperformancevariables. Therewas a
ignificant positive correlation in patients between post-error reac-
ion times and left and right IFC activation (r  .7, p  .02) and
etween go reaction times and right IFC activation (r .6, p .05)
nd a negative correlation between response variability and right
nferior parietal activation (r.7, p .02).
Successful Stop–GoContrast. No significant activation differ-
nces were observed between medication conditions.
NOVA Between-Group Comparisons in Brain Activation
etween Control Subjects and Boys with ADHDUnder Either
he Placebo or theMPH Conditions
Failed Stop–Go Contrast. Relative to control subjects, ADHD
atients under the placebo condition showed underactivation in
eft IFC and dorsomedial prefrontal cortices (dMFC) (including pre-
paredwith placebo in patientswith attention-deficit/hyperactivity disorder
-deficit/hyperactivity disorder comparingmethylphenidate andplacebo for
t of p .05. Methylphenidate comparedwith placebo enhanced activation
ex/insula, reaching into caudate andputamen, in left dorsolateral prefrontal
hanced under placebo compared withmethylphenidate. No within-groupcom
ntion
ntras
l cort
ere eninhibition contrast. The right side of the figure corresponds to the right side
www.sobp.org/journal
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wSMA), right premotor, superior and inferior parietal cortices, poste-
rior cingulate/precuneus, posterior thalamus, and bilateral inferior
temporo-occipital areas (Figure 2A, Table 3).
Under the MPH condition, ADHD patients did not differ from
controls in any of these regions.
Post-error slowing in ADHD patients under placebo, but not in
control subjects, was significantly positively correlated with activa-
tion in left IFC, premotor, dMFC, and thalamic underactivation clus-
ters (r .6 for all clusters, p .05) as well as with superior parietal,
occipital, and cerebellar activation (r .4, p .05). Standard devia-
ion of reaction times was correlated with dMFC activation in con-
rols (r .6, p .02).
Successful Stop–Go Contrast. Relative to control subjects,
DHD patients under the placebo condition showed underactiva-
ion in a right hemispheric network ofmedial temporal and inferior
arietal lobes, precuneus/posterior cingulate and cerebellum (Fig-
re 2B, Table 3). To test our hypothesis of IFC underactivation, we
eanalyzed the data at a more lenient p value of p  .002 for
oxelwise comparison. This elicited additional underactivation in
ight IFC, left and right subthalamic nuclei, and the pre-SMA (Table
and Figure S2 in Supplement 1).
Under the MPH condition, ADHD patients did not differ from
ontrol subjects in any of these regions.
Activation in posterior cingulate and lingual gyrus correlated
ignificantly positively with post-error go reaction times in ADHD
oys under placebo (r .6, p .3).
All groupdifference findings for both contrasts remained essen-
ially unchanged when IQ was covaried.
onjunction Analysis BetweenWithin-Group and
etween-Group ANOVAs
To test whether brain regions that were upregulated with MPH
elative to placebo within patients overlapped with brain regions
Table 2. Within-Group Analysis of Variance Differences in Brain Activation
Methylphenidate for the Inhibition Failure Condition
Brain Region Brodmann Area
Inhibition Failure Me
L Inferior Frontal Cortex/Insula/Putamen/Caudate 47
Inferior Prefrontal Cortex/Insula/Putamen 47
Caudate
Medial Frontal Gyrus 46
R Inferior Parietal Lobe/Precuneus 40/7
R Occipital Cortex 19
R Occipital Cortex 19
PlaceboMethy
L, left; R, right.ww.sobp.org/journalhat were reduced in patients under placebo relative to controls
nd then normalized with MPH, we performed a conjunction anal-
sis by determining the voxels where the within-group ANOVA
MPHplacebo inADHD) and the between-groupANOVA (control
ubjectsADHDplacebo)wereboth significant (42). Three clusters
merged, in left IFC (Talairach coordinates: 43, 7, 4), right SMA
Talairach coordinates: 7, 4, 59) and right inferior parietal lobe (Ta-
airach coordinates: 32,63, 42). Overlapping clusters are also indi-
ated in bold in Table 3 and shown in Figure 3.
iscussion
During error trials, ADHD boys under placebo compared with
ealthy control subjects showed significant underactivation in a
ypical error processing and performance monitoring network
omprising dMFC, left IFC, thalamus, posterior cingulate/precu-
eus, and inferior temporoparietal regions. Among patients, MPH
ompared with placebo significantly upregulated activation in
verlapping medial frontal, IFC, and parietal regions as well as the
enticular nucleus. Under MPH, brain activation differences be-
ween control subjects and ADHD patients were no longer ob-
erved. Reduced fronto-thalamo-parietal activation that was nor-
alized with MPH was, furthermore, negatively associated with
aster post-error reaction times in patients, which were trendwise
lowed with MPH.
During successful stop trials, ADHD boys showed underactiva-
ion in a right hemispheric network ofmedial temporal and inferior
arietal brain regions and, at a more lenient threshold, in small
lusters of bilateral IFC, thalamus, and pre-SMA. Although within-
atient comparison between MPH and placebo did not show sig-
ificant activation differences, all underactivations in patients rela-
ive to control subjects under placebo were normalized with a
ingle dose of MPH.
s with the Attention-Deficit/Hyperactivity Disorder Between Placebo and
alairach Coordinates (x,y,z) Number of Voxels Cluster p Value
henidate Placebo
32, 15, 2 43 .001
25, 14, 12 36 .0008
7, 4, 7 15 .0007
32, 33, 25 11 .0005
28, 59, 42 111 .0005
25, 92, 13 27 .001
43, 78, 7 46 .0006
idate: No Effect
Figure 2. Between-group analysis of variance compari-
son between healthy control boys and boys with atten-
tion-deficit/hyperactivity disorder (ADHD) under the pla-
cebo condition. Significantly reduced activation in boys
with ADHD under placebo compared with healthy com-
parison boys at family-wise error-corrected cluster-level
contrast ofp .05 for (A) failed stop trials and (B) success-
ful stop trials. No increased activation was observed in
ADHD boys compared with healthy control boys. Under
the methylphenidate condition, brain activation differ-
ences between groupswere no longer observed in any of
the two task conditions. The right side of the image corre-
sponds to the right side of the brain.in Boy
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pre-SMA andACC, is a typical region of error processing and perfor-
mancemonitoring in adults (37,43–48) and children (29,38,49). We
have previously found this region to be underactivated in children
with ADHD during oddball (50) and switch tasks (4). Errors indicate
violation of a reward prediction (i.e., positive performance) and
have been linked to midbrain dopamine (51). Normalization with
MPH of underfunctioning of this region in ADHD is in line with the
notion that phasic dopamine response modulates error-related
mesial frontal activation (52,53). These findings extendevidence for
upregulation with acute and chronic doses of MPH in previously
Table 3. Between-Group ANOVA Differences in Brain Activation Between C
Condition for the Contrast of Inhibition Failure and Successful Inhibition
Brain Region Brodmann Area
Inhibit
Controls AD
L Inferior Frontala 45/44
orsomedial Frontal Cortex/Pre-SMAa 6/8
R Premotor Cortex 6
Thalamus (Pulvinar)
Thalamus (Pulvinar)
Inferior Parietal Lobea 40
Superior Parietal Lobe 7
Posterior Cingulate 23
Precuneus 23/7
Precuneus/Superior Parietal Lobe 27
Inferior Temporal/Occipital Lobe 19/39
Occipital Gyrus 19
R Cerebellum
Success
Controls AD
Medial Temporal Lobe 21/22
medial temporal lobe/occipital 39/19
Lingual Gyrus 18
Inferior Parietal Lobe 7
Precuneus/Posterior Cingulate 7/31
erebellum Hemisphere
Inferior Frontal Gyrus/Insulab 47
L Insula/Inferior Frontalb 44
L and R Anterior Cingulateb 32
L Thalamus (Pulvinar)b
Thalamus (Pulvinar)b
R pre-SMAb 6/8
pre-SMAb 6/8
p value for ANOVA at family-wise error-corrected cluster-level contras
methylphenidate and healthy control children.
ADHD, attention-deficit/hyperactivity disorder; ANOVA, analysis of varia
aRegions that overlapped in the conjunction analysis between this AN
activation under methylphenidate than for placebo.
bClusters only observed at a more lenient voxel–wise p value of p  .00
control boys for either condition.
Figure 3. Conjunction analysis for the stop failure condition: common bra
within the attention-deficit/hyperactivity disorder group and which in addition
relative to control subjects and then normalized with methylphenidate. The righedicated patients with ADHD in a more rostral ACC location dur-
ng tasks of cognitive control (22,28,54).
Activation indMFCduringerrors triggers additional activation in
unctionally interconnected left IFC, as well as striatal, premotor,
ndparietal components of the errormonitoring system, leading to
ost-error performance adjustments (43–45,48). IFC underactiva-
ion is oneof themost consistent findings in fMRI studies inpatients
ith ADHD, with right IFC dysfunction typically observed during
nhibitory performance (7,8,11,55), in line with its role in inhibition
37,56), and left IFC during stop errors (4,29) as well as during
exible, selective, or sustained attention (4,9,26,50,57), in line with
l and ADHD Boys Under Either the Placebo or the Methylphenidate
ach Coordinates (x,y,z) Number of Voxels Cluster p Value
ailure
nder Placebo
47, 11, 9 78 .002
0, 11, 53 74 .001
40, 4, 31 35 .002
7, 26, 2 9 .002
10, 30, 7 9 .002
32, 59, 42 93 .005
22, 48, 59 8 .01
4, 48, 26 181 .005
26, 52, 42 56 .002
14, 44, 64 41 .005
43, 63, 2 73 .002
43, 70, 7 8 .002
29, 85, 18 39 .004
ibition
nder Placebo
43. Forty-one, 4 40 .0004
47, 63, 7 104 .0005
18, 85, 3 47 .001
32, 59, 48 27 .0007
11, 59, 31 88 .002
40, 59, 29 8 .003
34, 18, 0 5 .002
50, 11, 11 5 .002
4, 42, 18 9 .002
3, 25, 3 10 .002
6, 16, 3 8 .002
14, 11, 53 12 .001
3, 11, 53 12 .001
 .05. No differences were observed between boys with ADHD under
, left; R, right; SMA, supplementary motor area.
analysis and the within–patients ANOVA for areas that showed greater
ys with ADHD under placebo had no increased activation compared with
ivation clusters that were significantly upregulated with methylphenidateontro
Talair
ion F
HD u
ful Inh
HD U
t of p
nce; L
OVAin act
were underactivated in attention-deficit/hyperactivity disorder patients
t side of the image corresponds to the right side of the brain.
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wits role for performance monitoring (44,45,48,49) and saliency pro-
cessing (58,59). IFC dysfunction is furthermore a disorder-specific
neurofunctional deficit compared with patients with conduct
(6,50,57,60) and obsessive compulsive (4) disorders. MPH thus ap-
pears to modulate an important neurofunctional biomarker of
ADHD. The more predominantly left-hemispheric upregulation ef-
fect during errors may suggest a stronger effect of MPH on perfor-
mance monitoring than inhibitory function in ADHD. Left IFC up-
regulation has previously been observed in ADHD patients in the
context of an attention-demanding time discrimination task after
acute (27) and 6 weeks of MPH treatment during interference inhi-
bition (54). Structural studies have shown more normal cortical
thinning in left IFC in psychostimulant-medicated compared with
unmedicated ADHD children (61). Together, this raises the specula-
tion thatMPHmay have a lateralized upregulating effect on left IFC
structure and function.
Posterior thalamic regions have been associated both with mo-
tor response inhibition (62) and performance monitoring
(48,63,64). Thefinding thatMPHnormalizes activation in this region
is in line with speculation of this region’s involvement in the mod-
ulation of the dopaminergic error signal (63,65,66).
The fact that lower dMFC, IFC, and thalamic activation in ADHD
patients was associated with faster post-error slowing, both of
which were enhanced by MPH, reinforces the role of this network
for abnormal error monitoring in ADHD. Posterior cingulate and
precuneus are connected with MFC and parietal areas and form
part of the performancemonitoring network (47,49,67,68), mediat-
ing visual spatial attention to saliency (69,70) and the integration of
performance outcome with attentional modulation (48). The fact
that these regions were underactivated during both inhibition and
its failure is in linewith a generic attention role of these areas. In line
with this, we and others have previously observed underactivation
inADHDpatients in these regionsduring inhibitionerrors (4,6,8,60),
as well as during other salient stimuli such as oddball, novel or
incongruent targets (10,26,50,71,72).
Normalization with MPH of reduced activation in typical fronto-
parietal regions of saliency processing and performance monitor-
ing is consistentwith thedopamine-deficiencyhypothesis ofADHD
given that dopamine agonists enhance stimulus salience (73). It is
also in line with our previous findings of upregulation with MPH of
posterior cingulate/precuneus in the same group of medication
naive boys with ADHD during a target detection task, resulting in
improved attention (26), and during an attention demanding time
discrimination task (27). To our knowledge, normalization of infe-
rior parietal activationwithMPHhas only recently beenobserved in
ADHDpatients, in the context of sustained attention (26) and inter-
ference inhibition (54).
During successful stop trials, MPH also normalized underactiva-
tion in the cerebellum, which, together with subthalamic nucleus,
caudate, and IFG, forms a neurofunctional network of motor re-
sponse inhibition (38). These findings extend previous evidence for
cerebellum upregulation with MPH in ADHD patients during inter-
ference inhibition (54) and time estimation (27).
Within patients, MPH also enhanced activation of caudate and
putamen. This is in line with previous fMRI findings of caudate
upregulation in ADHD patients after acute and chronic doses of
MPH during inhibition and attention tasks (22,24,54) and is likely
associated with the known effect of MPH on striatal dopamine
transporter blockage (14,15).
The findings of more pronounced normalization effects of MPH
on abnormal performance monitoring than inhibition networks
could suggest that MPH enhances generic attention and perfor-
mance monitoring functions more than inhibitory capacity. This
ww.sobp.org/journalouldbe in linewith thebehavioral effect ofMPHofmodulatinggo
nd post-error reaction times, but not inhibition speed, which, fur-
hermore were correlated with the reduced frontothalamic error-
rocessing activation that was normalized with MPH. Relative to
ontrol subjects, patients only significantly differed in intrasubject
esponse variability. Small subject numbers, a relatively older child
roup, and fMRI task design restrictionsmayhavebeen responsible
orminorbehaviordifferences. Thefindingsofbraindysfunctions in
oys with ADHD and their normalization under the clinical dose of
PH despite minor performance differences and only trend-level
mprovements with MPH show that brain activation is more sensi-
ive thanperformance todetect both abnormalities andpharmaco-
ogic effects. This is in line with previous findings of marked brain
ysfunctions inADHDadolescents despite no stop task impairment
7,8,50) and higher sensitivity of brain activation than behavior to
how pharmacologic effects of MPH in ADHD (24,26–28,54,74).
MPHprevents the reuptakeof catecholamines fromthe synaptic
left by blocking dopamine andnorepinephrine transporters (DAT/
ET) (75,76), with higher affinity for the former (77,78). In healthy
dults, MPH blocks 60% to 70%of striatal DAT in a dose-dependent
anner, increasing extracellular levels of dopamine in striatum
75,79–82), as well as in frontal, thalamic, and temporal regions
83). The upregulating effects on basal ganglia, thalamic, and ante-
ior cingulateactivationwere therefore likelymediatedbymesolimbic
triatocingulate dopaminergic pathways known to modulate error
onitoring systems (63,64). In frontal regions, however,MPHupregu-
ates noradrenaline to the same or greater extent than dopamine
84–86), via reuptake inhibition of NET that clear up both dopamine
nd noradrenaline (85,87–89). The upregulating effects on frontal ac-
ivation, therefore, may have been mediated by enhanced catechol-
mine neurotransmission, in line with recent evidence that noradren-
line also plays a role in errormonitoring (66,90).
A limitation of the study is that patients were tested twice,
hereas control subjects were only scanned once, for ethical and
nancial reasons. Practice effects, however, were overcome by the
ounterbalanced design. Another limitation is the relatively small
ample size. Minimum numbers of 15 to 20 participants have been
uggested for fMRI studies (91). Repeated-measures designs, how-
ver, are statistically more powerful than independent data sets,
hich makes the within-subject ANOVAmore robust.
Toourknowledge, this is thefirststudytoshowthatasingledoseof
PH in ADHD upregulates and normalizes the underfunctioning of
MFC, left IFC, posterior cingulate, andparietal regions that in concert
lay an important role in error processing. The normalization findings
f these key regions of both performancemonitoring and ADHDdys-
unction reinforce theassociationbetweendopaminergicneurotrans-
ission abnormalities, ADHD, and poor performancemonitoring and
ayunderlie thebehavioral effects of improvingattentionand school
erformance in boyswith ADHD.
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